Trump Threatens Aircraft Tariffs as U.S.-Canada Jet Certification Dispute Escalates 
Nvidia Confirms Major OpenAI Investment Amid AI Funding Race 
Panama Supreme Court Voids Hong Kong Firm’s Panama Canal Port Contracts Over Constitutional Violations 
Panama Supreme Court Voids CK Hutchison Port Concessions, Raising Geopolitical and Trade Concerns 
CSPC Pharma and AstraZeneca Forge Multibillion-Dollar Partnership to Develop Long-Acting Peptide Drugs 
Nvidia’s $100 Billion OpenAI Investment Faces Internal Doubts, Report Says 
Using the Economic Calendar to Reduce Surprise Driven Losses in Forex 
Sandisk Stock Soars After Blowout Earnings and AI-Driven Outlook 
Elon Musk’s SpaceX Explores Merger Options With Tesla or xAI, Reports Say 
OpenAI Reportedly Eyes Late-2026 IPO Amid Rising Competition and Massive Funding Needs 
Chinalco and Rio Tinto Acquire Controlling Stake in Brazil’s CBA for $903 Million 
Apple Earnings Beat Expectations as iPhone Sales Surge to Four-Year High 
Elon Musk’s Empire: SpaceX, Tesla, and xAI Merger Talks Spark Investor Debate 
Saks Global to End Saks on Amazon Partnership Amid Bankruptcy Restructuring 
LOS ANGELES, May 25, 2017 -- Lundin Law PC, a shareholder rights firm, announces the filing of a class action lawsuit against Akari Therapeutics, Plc (“Akari” or the “Company”) (Nasdaq:AKTX) concerning possible violations of federal securities laws between March 30, 2017 and May 11, 2017 inclusive (the “Class Period”). Investors who purchased or otherwise acquired shares during the Class Period should contact the firm prior to the July 11, 2017 lead plaintiff motion deadline.
To participate in this class action lawsuit, click here.
You can also call Brian Lundin, Esq., of Lundin Law PC, at 888-713-1033, or you can e-mail him at [email protected].
No class has been certified in the above action yet. Until a class is certified, you are not considered represented by an attorney. You may also choose to do nothing and be an absent class member.
According to the Complaint, throughout the Class Period, Akari made materially false and/or misleading statements, and/or failed to disclose materially adverse facts about its business, operations, and prospects. On April 26, 2017, Edison Research Ltd. issued a report on the Company called “Akari’s Coversin matches Soliris in Phase II.” The next day it was announced that the report was withdrawn due to “material inaccuracies.” On May 11, 2017, Akari announced that CEO Dr. Gur Roshwalb has been placed on administrative leave while the Board of Directors reviews whether Dr. Roshwalb and other executives were involved with the materially inaccurate research report. When this information was announced, Akari shares fell in value, which harmed investors according to the Complaint.
Lundin Law PC was founded by Brian Lundin, a securities litigator based in Los Angeles dedicated to upholding shareholders’ rights.
This press release may be considered Attorney Advertising in certain jurisdictions under the applicable law and ethical rules.
Contact: Lundin Law PC Brian Lundin, Esq. Telephone: 888-713-1033 Facsimile: 888-713-1125 [email protected] http://lundinlawpc.com/
